Drug Interaction Guidance for Weight‑Loss Medications with Sertraline and Quetiapine
Orlistat – Interaction Profile and Safety
- Orlistat does not produce pharmacokinetic interactions with sertraline or quetiapine because it acts locally in the gastrointestinal tract and has minimal systemic absorption, resulting in no alteration of antidepressant or antipsychotic plasma levels. 3
- No CYP450 (including CYP2D6) metabolism or inhibition occurs with Orlistat, so concurrent use with serotonergic or antipsychotic agents does not increase drug concentrations. 1
- The principal safety issue with Orlistat is malabsorption of fat‑soluble vitamins (A, D, E, K), not drug‑drug interactions, necessitating vitamin supplementation when used long‑term. 1, 2
- The American Gastroenterological Association (AGA) conditionally recommends against routine use of Orlistat for obesity because weight loss is modest (approximately 2.8 – 4.8 % of baseline body weight) and gastrointestinal adverse effects are common; this reflects a conditional recommendation based on moderate‑quality evidence. 1, 2
- When other weight‑loss agents are contraindicated (e.g., naltrexone‑bupropion with sertraline), Orlistat becomes a reasonable alternative because of its favorable interaction profile. 3
Phentermine‑Topiramate – Efficacy and Monitoring
- In patients receiving sertraline and/or quetiapine, phentermine‑topiramate provides the greatest weight‑loss efficacy among the three agents discussed, achieving roughly 10.9 % mean body‑weight reduction at the higher approved dose, with no absolute pharmacokinetic contraindication. 3, 1
Comparative Effectiveness and Positioning
- Second‑line option: Orlistat is the safest regarding drug‑interaction risk but yields the least weight‑loss benefit compared with phentermine‑topiramate, making it appropriate when cardiovascular or seizure‑threshold concerns limit use of phentermine‑topiramate. 1, 2